---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-306737"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-07-17T11:05:41+00:00"
generated_at: "2026-07-17T11:10:06.162715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kalaris reports positive expanded Phase 1a data for TH103 in nAMD; 29% no retreatment in 6 months

## Summary
- Expanded Phase 1a SAD dataset: 17 treatment-naïve + 3 treatment-experienced patients; all 20 completed 6-month follow-up.
- After single TH103 injection, 41% of treatment-naïve patients retreatment at ≥4 months, 29% no anti-VEGF treatment in 6 months.
- Mean 9.2-letter BCVA improvement, 118µm CST reduction, 93% reduction in intraretinal fluid at one month.
- TH103 plasma Cmax 27- to 53-fold lower vs leading anti-VEGF agents on molar equivalence basis.
- No IOI at 2.5 mg with improved manufacturing; Phase 1b/2 enrolling, initial data expected 1H 2027.

## SEC filing metadata
- accession: 0001193125-26-306737
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-07-17T11:05:41+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/0001193125-26-306737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-306737
- JSON: https://secwatch.observer/filing/0001193125-26-306737.json
- Plain text: https://secwatch.observer/filing/0001193125-26-306737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.